» Articles » PMID: 39598249

Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care

Abstract

Breast cancer is the most prevalent cancer worldwide, affecting both low- and middle-income countries, with a growing number of cases. In 2024, about 310,720 women in the U.S. are projected to receive an invasive breast cancer diagnosis, alongside 56,500 cases of ductal carcinoma in situ (DCIS). Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life. About 65% of women with the and 45% with the gene variants develop breast cancer by age 70. While these genes account for 5% of breast cancers, their prevalence is higher in certain populations. Advances in early detection, personalised medicine, and AI-driven diagnostics are improving outcomes by enabling a more precise analysis, reducing recurrence, and minimising treatment side effects. Our paper aims to explore the vast applications of artificial intelligence within the diagnosis and treatment of breast cancer and how these advancements can contribute to elevating patient care as well as discussing the potential drawbacks of such integrations into modern medicine. We structured our paper as a non-systematic review and utilised Google Scholar and PubMed databases to review literature regarding the incorporation of AI in the diagnosis and treatment of non-palpable breast masses. AI is revolutionising breast cancer management by enhancing imaging, pathology, and personalised treatment. In imaging, AI can improve the detection of cancer in mammography, MRIs, and ultrasounds, rivalling expert radiologists in accuracy. In pathology, AI enhances biomarker detection, improving and assessments. Personalised medicine benefits from AI's predictive power, aiding risk stratification and treatment response. AI also shows promise in triple-negative breast cancer management, offering better prognosis and subtype classification. However, challenges include data variability, ethical concerns, and real-world validation. Despite limitations, AI integration offers significant potential in improving breast cancer diagnosis, prognosis, and treatment outcomes.

Citing Articles

Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer.

Martinez-Ramirez J, Carmona C, Ramirez-Exposito M, Martinez-Martos J Life (Basel). 2025; 15(2).

PMID: 40003620 PMC: 11856414. DOI: 10.3390/life15020211.


Effect of the COVID-19 Pandemic on the Management of Breast Cancer Patients.

Dalda Y, Akbulut S, Kucukakcali Z, Ogut Z, Dalda O, Alan S J Clin Med. 2025; 13(24.

PMID: 39768596 PMC: 11678252. DOI: 10.3390/jcm13247673.


Integrated analysis of cell cycle and p53 signaling pathways related genes in breast, colorectal, lung, and pancreatic cancers: implications for prognosis and drug sensitivity for therapeutic potential.

Khan J, Ghosh P, Bajpai U, Dwivedi K, Saluja D Discov Oncol. 2024; 15(1):832.

PMID: 39715832 PMC: 11666898. DOI: 10.1007/s12672-024-01712-8.


Evaluation of the Influence of Extract on Cognitive Functions and Hippocampal BDNF Expression.

Lechkova B, Shishmanova-Doseva M, Benbassat N, Gevrenova R, Atanassova P, Penkova N Molecules. 2024; 29(23).

PMID: 39683883 PMC: 11643275. DOI: 10.3390/molecules29235723.

References
1.
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z . Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. J Pathol. 2023; 260(5):498-513. PMC: 10518802. DOI: 10.1002/path.6155. View

2.
McCaffrey C, Jahangir C, Murphy C, Burke C, Gallagher W, Rahman A . Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer. Expert Rev Mol Diagn. 2024; 24(5):363-377. DOI: 10.1080/14737159.2024.2346545. View

3.
Ouyang B, Shan C, Shen S, Dai X, Chen Q, Su X . AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer. Nat Commun. 2024; 15(1):7560. PMC: 11364624. DOI: 10.1038/s41467-024-51980-9. View

4.
Scott C, Jenkins M, Southey M, Davis T, Leary J, Easton D . Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet. 2003; 112(5-6):542-51. DOI: 10.1007/s00439-003-0908-6. View

5.
Dembrower K, Crippa A, Colon E, Eklund M, Strand F . Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health. 2023; 5(10):e703-e711. DOI: 10.1016/S2589-7500(23)00153-X. View